Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix

Cancer

Volumn 119, Issue 21, 2013, Pages 3776-3783

  Wright, Alexi A ^a,b   Howitt, Brooke E ^b,c   Myers, Andrea P ^a,b   Dahlberg, Suzanne E ^a,d   Palescandolo, Emanuele ^a,b   Van Hummelen, Paul ^a,b,e   Macconaill, Laura E ^a,b,e   Shoni, Melina ^b   Wagle, Nikhil ^a,b,e   Jones, Robert T ^a   Quick, Charles M ^b,c   Laury, Anna ^b,c   Katz, Ingrid T ^b,c   Hahn, William C ^a,b,e   Matulonis, Ursula A ^a,b   Hirsch, Michelle S ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

adenocarcinoma; cervical cancer; DNA mutational analysis; EGFR; human papillomavirus; KRAS; mutation; PIK3CA; somatic mutations; squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MASSIVE PARALLEL SEQUENCING; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA GENE; PRIORITY JOURNAL; SOMATIC MUTATION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WART VIRUS;

ADENOCARCINOMA; CERVICAL CANCER; DNA MUTATIONAL ANALYSIS; EGFR; HUMAN PAPILLOMAVIRUS; KRAS; MUTATION; PIK3CA; SOMATIC MUTATIONS; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENES, ERBB-1; GENOTYPE; HUMANS; MIDDLE AGED; MUTATION; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; SEER PROGRAM; UTERINE CERVICAL NEOPLASMS;

EID: 84886094737     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28288     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S,. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004; 100: 1035-1044.
3. Galic V, Herzog TJ, Lewin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol. 2012; 125: 287-291.
4. Oka K, Nakano T, Hoshi T,. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Cancer. 1996; 77: 2280-2285.
5. Eifel PJ, Burke TW, Morris M, Smith TL,. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995; 59: 38-44.
6. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH,. Outcomes after radical hysterectomy in patients with early stage adenocarcinoma of uterine cervix. Br J Cancer. 2010; 102: 1692-1698.
7. Lee YY, Choi CH, Kim TJ, et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol. 2011; 120: 439-443.
8. Arias-Pulido H, Joste N, Chavez A, et al. Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer. 2008; 18: 749-754.
9. Iida K, Nakayama K, Rahman MT, et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer. 2011; 105: 420-427.
10. Janku F, Lee JJ, Tsimberidou AM, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers [serial online]. PLoS One. 2011; 6: e22769.
11. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD,. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer. 2006; 118: 1877-1883.
12. McIntyre JB, Wu J, Craighead PS, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2013; 128: 409-414.
13. Kim TJ, Lee JW, Song SY, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer. 2006; 94: 1678-1682.
14. Pappa KI, Choleza M, Markaki S, et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol. 2006; 100: 596-600.
15. Kang S, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM,. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol. 2007; 105: 662-666.
16. Wegman P, Ahlin C, Sorbe B,. Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy. Int J Gynecol Cancer. 2011; 21: 86-91.
17. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples [serial online]. PLoS One. 2009; 4: e7887.
18. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31: 213-219.
19. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), based on November 2011 SEER data submission, posted to the SEER website April 2012. Bethesda, MD: National Cancer Institute; 2012. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed June 9, 2013.
20. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE,. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009; 101: 475-487.
21. Schwartz SM, Daling JR, Shera KA, et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol. 2001; 19: 1906-1915.
22. Wingo SN, Gallardo TD, Akbay EA, et al. Somatic LKB1 mutations promote cervical cancer progression [serial online]. PLoS One. 2009; 4: e5137.
23. Halle C, Lando M, Svendsrud DH, et al. Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer. Clin Cancer Res. 2011; 17: 5501-5512.
24. Lai CH, Chang CJ, Huang HJ, et al. Role of human papillomavirus genotype in prognosis of early stage cervical cancer undergoing primary surgery. J Clin Oncol. 2007; 25: 3628-3634.
25. Kang WD, Kim CH, Cho MK, et al. HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy. Gynecol Oncol. 2011; 121: 546-550.
26. Courtney KD, Corcoran RB, Engelman JA,. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28: 1075-1083.
27. Janku F, Wheler JJ, Naing A, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013; 73: 276-284.
28. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012; 18: 2257-2268.
29. Henken FE, Banerjee NS, Snijders PJ, et al. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro [serial online]. Mol Cancer. 2011; 10: 71.
30. Schwarz JK, Payton JE, Rashmi R, et al. Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res. 2012; 18: 1464-1471.
31. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30: 777-782.
32. Xia S, Zhao Y, Yu S, Zhang M,. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother Radiopharm. 2010; 25: 317-323.
33. Smith JC, Brooks L, Hoff PM, et al. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. Eur J Cancer. 2013; 49: 2424-2432.
34. Bruera G, Cannita K, Di Giacomo D, et al. Worse prognosis of KRAS c. 35 G>A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) [serial online]. BMC Med. 2013; 11: 59.
35. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005; 92: 131-139.
36. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486: 532-536.
37. Corcoran RB, Cheng KA, Hata AN, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013; 23: 121-128.
38. Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature. 2013; 497: 638-642.
39. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013; 14: 38-47.
40. Noske A, Schwabe M, Weichert W, et al. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas [serial online]. BMC Cancer. 2011; 11: 294.
41. Buitrago-Perez A, Garaulet G, Vazquez-Carballo A, Paramio JM, Garcia-Escudero R,. Molecular signature of HPV-induced carcinogenesis: pRb, p53 and gene expression profiling. Curr Genomics. 2009; 10: 26-34.